Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 241

Results For "company"

4867 News Found

Eugia Pharma receives USFDA Approval for Icatibant Injection
Drug Approval | August 16, 2023

Eugia Pharma receives USFDA Approval for Icatibant Injection

This is the 166th ANDA out of Eugia Pharma Speciality Group facilities


Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr
News | August 13, 2023

Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr

Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023


Krsnaa Diagnostics posts Q1 FY24 consolidated PAT at Rs. 14.64 Cr
News | August 13, 2023

Krsnaa Diagnostics posts Q1 FY24 consolidated PAT at Rs. 14.64 Cr

Krsnaa Diagnostics has reported total income of Rs. 143.80 crores during the period ended June 30, 2023


Panacea Biotec posts Q1 FY24 consolidated PAT at Rs. 10.98 Cr
News | August 13, 2023

Panacea Biotec posts Q1 FY24 consolidated PAT at Rs. 10.98 Cr

Panacea Biotec has reported total income of Rs. 135.27 crores during the period ended June 30, 2023


WuXi XDC and Boostimmune sign MoU for integrated services
News | August 13, 2023

WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform


Gujarat Themis Biosyn posts Q1 FY24 PAT at Rs. 17.72 Cr
News | August 12, 2023

Gujarat Themis Biosyn posts Q1 FY24 PAT at Rs. 17.72 Cr

Gujarat Themis Biosyn has reported total income of Rs. 50.66 crores during the period ended June 30, 2023


IPCA Laboratories posts Q1 FY24 consolidated PAT at Rs. 162.82 Cr
News | August 12, 2023

IPCA Laboratories posts Q1 FY24 consolidated PAT at Rs. 162.82 Cr

IPCA Laboratories has reported total income of Rs. 1632.43 crores during the period ended June 30, 2023


SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr
News | August 10, 2023

SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr

The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023


Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr
News | August 10, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24


Hester Biosciences posts Q1 FY24 consolidated PAT at Rs. 5.86 Cr
News | August 10, 2023

Hester Biosciences posts Q1 FY24 consolidated PAT at Rs. 5.86 Cr

Hester Biosciences has reported total income of Rs. 88.99 crores during the period ended June 30, 2023